• Explore /
  • Poster
  • / A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).

A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).

Abstract Poster

Authors

null

Samuel A Funt

Memorial Sloan Kettering Cancer Center, New York, NY

Samuel A Funt , Andrea Knezevic , Benjamin A Freeman , Mary Bolos , Victoria Martorana , Mark Donoghue , Shah Khan , Harleen Singh , Maria Bromberg , Colleen Quinlan , Maryann Carousso , Achim A. Jungbluth , Sujata Patil , Neil J. Shah , Chung-Han Lee , Deaglan Joseph McHugh , Hikmat A. Al-Ahmadie , Darren R. Feldman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Germ Cell/Testicular Cancer

Clinical Trial Registration Number

NCT03158064

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5040)

DOI

10.1200/JCO.2023.41.16_suppl.5040

Abstract #

5040

Poster Bd #

134

Abstract Disclosures

Similar Posters

First Author: David Tougeron

First Author: Anna Jansson

First Author: Stefanie Zschaebitz

First Author: Federico Losco